🇺🇸

US SEC Filing Intelligence

· daily

US Corporate Distress Financial Stress SEC Filings — March 20, 2026

Across 41 filings in the USA Corporate Distress & Bankruptcy stream, a dominant theme is acute small-cap distress with 13 companies (e.g., GoHealth, Quince Therapeutics, MaxCyte, NextNRG, Ernexa, Tivic, Heritage/IPST, Faraday Future, Tela Bio, Alzamend Neuro) receiving Nasdaq deficiency notices for bid price < $1.00 over 30 days, MVLS/equity shortfalls, or audit committee issues, risking delisting by Sep 2026; Zynex confirmed Ch11 reorganization with equity cancellation (no recovery for 30.8M shares). Period-over-period trends show revenue declines (Beasley Broadcast -8.7% CAGR FY23-25 to $206M, audio -11.8%), but some improvements like Spruce Biosciences net loss -26% YoY to $39M FY25 and Embecta/Prestige accretive M&A. Forward-looking catalysts cluster in H1-Q3 2026: merger closings (KORE $9.25/share, Dillard's), compliance deadlines (180 days to Sep), Zynex emergence by Mar31; financings (TG Therapeutics $750M term loan, Fortive $2B revolver) signal liquidity support amid distress. Capital allocation leans defensive (debt paydowns, no dividends/buybacks noted except Fair Isaac $1B notes for repurchases), with insider reliance (Perfect Moment $5M chairman loans extended). Portfolio-level: Biotech/healthcare outliers in delisting risks (8/13), while consumer/energy M&A bucks trend; implications include short opportunities in non-compliant microcaps, long setups in turnaround financings/M&A.

41 high priority 41 total filings
· daily

US SEC Trading Suspension Halt Orders — March 20, 2026

A cluster of 11 small-cap companies, predominantly in biotech and healthcare (7/11), received Nasdaq deficiency notices between March 16-20, 2026, signaling acute distress in microcap listings with uniformly negative sentiment and high materiality (avg 9.3/10). Dominant theme: 9/11 failed minimum bid price requirement (<$1.00 for 30 consecutive business days), alongside MVLS shortfalls (GoHealth <$35M, Quince <$50M), low stockholders' equity (Alzamend $2.2M vs $2.5M min), and one audit committee violation (Lifeward <3 members). No enriched period-over-period financial improvements noted; implied QoQ stock price declines drove all bid failures over recent 30-day windows. Compliance periods standardize at 180 days to ~September 14-16, 2026, creating a portfolio-level delisting cliff, with 2 firms (Ernexa, Heritage) ineligible due to recent reverse splits, heightening urgency via hearings. Absent positive insider activity, capital allocation, or operational metrics, this wave underscores small-cap weakness amid potential funding droughts, risking mass OTC transfers, liquidity evaporation, and 20-50% further drawdowns.

11 high priority 11 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — March 20, 2026

The USA Bankruptcy & Insolvency intelligence stream highlights a single critical development: Zynex Inc.'s Chapter 11 reorganization plan confirmation on March 19, 2026, marking the culmination of proceedings initiated December 15, 2025, with emergence expected by March 31, 2026. All 30,781,021 existing common shares are cancelled with zero recovery for equity holders, transferring 100% ownership (approximately 1,000 new shares) to the Plan Sponsor and providing DIP Lenders $10M in takeback debt. No period-over-period financial trends are detailed in the filing, but the Nasdaq delisting (effective February 2, 2026) and OTC trading as ZYXIQ underscore speculative risks and total equity wipeout. Market implications include complete shareholder value destruction, heightened volatility in OTC trading, and a bearish sentiment (rated negative, materiality 10/10). Portfolio-level patterns are limited to this filing, but it exemplifies ongoing corporate insolvency pressures in the medical device sector, with no insider activity, capital allocation, or forward guidance beyond plan effectiveness noted.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 20, 2026

Across 38 SEC 8-K filings on USA Board Room Changes from March 16-20, 2026, the dominant theme is high executive and director turnover, with 24 resignations/retirements (mostly neutral voluntary exits citing no disagreements) versus 14 appointments/promotions, signaling routine board refreshes amid stable operations but potential leadership gaps in tech, biotech, and financials. Positive hires bring deep sector expertise (e.g., ex-Coinbase CFO at Streamex, Dycom ex-CEO at Centuri), while negatives include a director resignation over financial planning disputes at American Picture House and a criminal indictment impacting Super Micro executives. No uniform period-over-period financial trends emerge as filings focus on governance, but isolated signals like Nu Skin's interim CFO crediting YoY EPS gains from cost cuts and BranchOut's retroactive salary hikes post-growth highlight pockets of operational strength. Materiality skews high (avg 6/10) for CEO/CFO shifts (12 cases), implying short-term execution risks but long-term strategic upgrades. Portfolio-level pattern: neutral sentiment in 70% of filings suggests low disruption risk, but watch clustered director retirements ahead of 2026 AGMs for governance evolution. Market implication: opportunities in experienced hire turnarounds, risks in unresolved successions.

38 high priority 38 total filings
· daily

US Merger & Acquisition SEC Filings — March 20, 2026

The 12 filings reveal a surge in SPAC activity with 6 new IPOs or post-IPO events (SUMA, BHAV, Muzero, Fifth Era, Cayson, Pelican) and de-SPAC mergers advancing rapidly, including Pelican-Greenland closing March 24 and Nexstar's completed TEGNA acquisition on March 19, signaling robust M&A momentum in a tight window (March 12-24). Period-over-period trends show outlier strength in Merlin Labs (Inflection Point target) with 515% YoY revenue growth to $7.6M despite 35% wider net losses to $74.8M from opex and warrant surges, while B&G Foods' $110M Del Monte acquisition projects immediate EPS accretion ($0.08-0.12) at 5.5x EBITDA multiple. High redemptions (63% or 7.56M shares, $77.7M) in Pelican highlight cash drain risks in de-SPACs, contrasting full over-allotment exercises in SUMA (+2.25M units) and BHAV's $100M IPO. Media sector consolidation via Nexstar-TEGNA and TEGNA governance tweaks underscores strategic M&A, with neutral governance shifts in Horizon Quantum and Solaris financing potential Genco buy. Overall, bullish SPAC pipeline but mixed sentiment from redemptions and loss trends implies selective opportunities pre-close.

12 high priority 12 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 20, 2026

Overnight SEC filings reveal robust M&A and SPAC activity, with healthcare deals like Prestige's $1.045B Breathe Right acquisition and Embecta's £150M Owen Mumford buyout signaling sector consolidation, while SPAC mergers (CoinShares, Pelican/Greenland, Einride/Legato) advance amid heavy redemptions (Pelican 63%). Revenue growth dominates period comparisons across 12/50 filings, averaging +80% YoY (e.g., Firefly +163%, Aeva +99%, Cellectis +62%), but 8/12 show widening net losses (avg +40%) due to R&D/opex surges and yield compression in BDCs (avg -0.9%). Margin expansions stand out (QIAGEN gross +1,330bps to 62.2%), contrasting compression elsewhere; activist pressure mounts on Lululemon (Wilson 8.4% stake, criticizing flat FY2026 outlook). Capital allocation leans toward buybacks (News Corp $1B program) and financing (Firefly $1.3B inflows), with forward catalysts clustered in late March (merger closings) and April (earnings, meetings). Portfolio-level: Tech/AI/space names outperform on revenue but lag on profitability; BDCs grow assets +72-83% but face yield/margin erosion. Actionable: Favor accretive M&A targets, monitor SPAC post-merger liquidity.

38 high priority 12 medium 50 total filings
· daily

DHS Homeland Security Contracts — March 19, 2026

DHS stream reveals $473M in active contracts dominated by CBP border security hardware (60% of value) and IT sustainment, with $186M largest to Rapiscan Systems (OSI Systems sub) for multi-energy portals. All five awards signal bullish multi-year revenue for detection firms and IT providers, with 40-70% already outlayed indicating execution momentum. Potential extensions to 2033 and $183M+ in unexercised options offer substantial upside amid firm fixed price structures.

5 total filings
· daily

VA Healthcare & Services Contracts — March 19, 2026

VA awarded $381M in contracts signaling robust demand for health IT infrastructure (Oracle, Deloitte) and recurring medical supplies (Medline), with $900M+ in total potential via options. Medline's back-to-back Jan/Feb 2026 awards ($138M total) highlight predictable prime vendor revenue, while IT/cyber deals offer multi-year upside to 2029. All firm-fixed-price structures favor incumbents but expose to cost risks; monitor outlays for execution momentum.

4 total filings
· daily

NASA & Space Contracts Intelligence — March 19, 2026

NASA's $85.4M obligated delivery order to Caltech (nonprofit) for JPL's PO.DAAC-2 operations reflects steady, non-competed funding for space science R&D, with $72.4M (85%) already outlayed from an $89.6M ceiling. Neutral signal limits direct equity upside, but $4.2M unexercised options and 2026 expiry offer monitoring points for continuity. Single-contract period shows concentration in JPL FFRDC support amid potential NASA priority shifts.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — March 19, 2026

Federal IT & Cybersecurity obligations totaled $1.66B across 7 contracts, with Leidos capturing 64% ($1.06B) from SSA for multi-year IT management, underscoring civilian agency demand. VA and DHS account for 45% of value via EHR interfaces, cyber transformation, and HR/infra support, providing revenue visibility to 2029. All signals bullish with $1.1B in potential options uplift, though firm fixed price structures pose execution risks.

7 total filings
· daily

New Federal Contractors — March 19, 2026

New federal contracts totaling $2.9B over March 19, 2026, underscore robust demand for IT services (e.g., Leidos' $1.06B SSA award) and security/detection systems (DHS/CBP wins), with 16/18 bullish signals dominated by long-term deals featuring $2B+ in potential option upside. Public firms like Leidos, General Dynamics, and OSI Systems (Rapiscan) gain multi-year revenue visibility through 2029+, while VA monthly medical supply awards to Medline signal recurring demand. Neutral signals limited to nonprofits (Caltech, Refugees Committee) with minimal equity impact.

18 total filings
· daily

Significant Contract Modifications ($10M+) — March 19, 2026

This single-day snapshot reveals $2.9B in significant federal contract modifications, dominated by IT services ($1.6B+ across top awards) signaling sustained government demand amid fiscal 2026 planning. Leidos captures 38% of value with two mega-awards ($1.13B total), bolstering defense/IT peers like General Dynamics and Oracle, while DHS/VA healthcare and security contracts provide multi-year revenue backstops through 2033. Investors should prioritize unexercised options ($1.5B+ potential) and extensions for upside, tempered by firm-fixed-price execution risks.

18 total filings
· daily

Contract Deobligations Alert — March 19, 2026

This one-day Contract Deobligations Alert reveals $2.9B in sustained federal obligations across 18 contracts, predominantly bullish for IT/services firms with Leidos capturing 39% ($1.13B total) via SSA and DHS awards. Long-term revenue visibility dominates, with 15 contracts extending beyond 2026 (up to 2033) and $2.1B+ in unexercised options signaling upside. Risks cluster around firm fixed price exposure (12/18 contracts) amid high outlays ($1.7B+ already spent), favoring public defense/IT names like Leidos, General Dynamics, and Oracle over nonprofits.

18 total filings
· daily

Contract Option Exercises — March 19, 2026

This snapshot reveals $2.9B in contract option exercises dominated by bullish signals (16/18) in IT services and security equipment, with Leidos securing the largest $1.1B SSA award and DHS/CBP driving 5 contracts totaling $473M. Public companies like Leidos (LDOS), General Dynamics (GD), OSI Systems (OSIS), and Oracle (ORCL) benefit from multi-year revenue visibility through 2029+, though firm fixed price (FFP) structures pose execution risks on 12/18 awards. Unexercised options exceed $2B across the portfolio, signaling medium-term growth potential amid steady federal demand in health IT, border security, and medical logistics.

18 total filings
· daily

All HHS Contracts — March 19, 2026

Two bullish HHS contracts totaling $414.7M obligated (potential $670.6M with options) signal multi-year revenue stability for health services providers via cost-plus structures minimizing risk. Wisconsin Physicians Service dominates with $319M CMS Medicare admin award, while Charles River adds $96M NIH preclinical support, highlighting HHS outsourcing trends. Unexercised options offer $252M upside amid extensions to 2028-2029.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — March 19, 2026

Five mega contracts totaling $1.86B underscore strong federal demand for IT and health services, with Leidos securing the largest $1.06B SSA deal amid 82% outlay progress. All awards are bullish, featuring long durations (avg. potential end 2028+), $1.36B in combined unobligated options, and focus on civilian agencies (SSA, CMS, VA, DHS, Education). Public parents Leidos Holdings, OSI Systems, Oracle, and General Dynamics gain multi-year revenue visibility, though firm-fixed pricing dominates (4/5 contracts).

5 total filings
· daily

High-Value Federal Grants ($5M+) — March 19, 2026

This one-day snapshot of 18 high-value federal contracts totaling $2.9B underscores bullish momentum for IT services and health/security contractors, with Leidos securing the largest $1.1B combined awards from SSA and DHS. Firm fixed price structures dominate (12/18), offering revenue visibility but execution risks, while options provide $2B+ upside potential across portfolios. Institutional investors should prioritize public equities like Leidos (LDOS), OSI Systems (OSIS), and General Dynamics (GD) for steady gov revenue amid long-term extensions to 2033.

18 total filings
· daily

General Federal Contracts — March 19, 2026

Leidos dominates with a $1.06B SSA IT contract (37% of total value), signaling robust civilian IT demand and multi-year revenue stability amid $2.9B in awards. DHS/CBP and VA drive security/IT and medical supply contracts, with 16/18 bullish signals highlighting long-term options worth $2B+ upside. Firm fixed price structures prevail (70% of contracts), exposing winners to cost risks but locking in predictable cash flows through 2026-2033.

18 total filings
· daily

All NASA Contracts — March 19, 2026

NASA's $85.4M obligation to California Institute of Technology for PO.DAAC-2 operations signals stable funding for space science data archiving via JPL FFRDC, with $72.4M already outlayed and $4.2M in unexercised options. As a non-competed, nonprofit contract ending 2026-09-30, it offers neutral direct equity impact but underscores continuity in physical oceanography R&D. Investors face execution risks from task order dependence amid potential NASA priority shifts, with extension potential warranting monitoring.

1 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 19, 2026

Across 50 filings in the USA S&P 500 Consumer Staples stream (though diverse with funds, biotechs, REITs), proxy statements dominate (24/50, neutral sentiment) signaling robust governance ahead of clustered April-May 2026 annual meetings. Financial reporters (10-K/8-K, 18/50) show mixed YoY revenue growth averaging +25% (e.g., Vericel +20% CAGR, Satellogic +38%, electroCore +27%) but persistent net losses narrowing in 7/12 cases (e.g., SentinelOne op inc positive swing). Margin trends mixed with expansions (Signet adj op inc +3.4% FY, Vericel gross 74%) offset by compressions (Signet Q4 -60bps). Capital allocation leans positive: dividend hikes (Signet +17% to $0.35/sh, Modiv $0.10/mth), buybacks (Mount Logan $10M program), accretive M&A (Mount Logan +30% FRE). Forward guidance cautious (Signet FY27 SSS -1.25% to +2.5%) amid Q4 softness, but clinical catalysts in biotechs. Portfolio-level: Stable dividends vs reinvestment, low insider trading signals conviction, watch proxy outcomes and Q1 earnings for consumer resilience.

29 high priority 21 medium 50 total filings